# Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

> **NCT02039687** · PHASE2 · COMPLETED · sponsor: **Araim Pharmaceuticals, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Neuropathy of Sarcoidosis

## Interventions

- **DRUG:** ARA 290
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02039687
- **Lead sponsor:** Araim Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-01
- **Final completion:** 2015-02
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2017-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02039687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02039687, "Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02039687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*